PMID- 29423118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 3
DP  - 2018 Jan 9
TI  - The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for 
      pretreated advanced NSCLC: a meta-analysis.
PG  - 4239-4248
LID - 10.18632/oncotarget.23279 [doi]
AB  - Antibodies against the immune checkpoint proteins PD-1 and PD-L1 are novel 
      therapeutic drugs for the treatment of advanced non-small cell lung cancer 
      (NSCLC). Many clinical trials involving these drugs achieved breakthroughs in 
      patients previously treated for advanced NSCLC. However, the results of these 
      clinical studies are not consistent. In this report, we performed a meta-analysis 
      to assess the efficacy and safety of anti-PD-1/PD-L1 antibodies compared with 
      docetaxel treatment for advanced NSCLC patients from 5 randomized clinical 
      trials. We demonstrated that the patients in anti-PD-1/PD-L1 antibody therapy 
      groups had significantly longer overall survival (OS) (HR = 0.69, 95% CI 
      0.63-0.75, P < 0.05) and progression-free survival (PFS) (HR = 0.76, 95% CI 
      0.63-0.92, P < 0.05) than those in chemotherapy groups, especially PD-L1 positive 
      patients. Anti-PD-1/PD-L1 antibodies improved the objective response rate (ORR) 
      compared with docetaxel (OR = 1.64, 95% CI 1.19-2.26, p < 0.05). In addition, the 
      anti-PD-1/PD-L1 antibody therapy had fewer treatment-related adverse events (AEs) 
      (OR = 0.33, 95% CI 0.28-0.39, P < 0.05) than docetaxel, especially the grade >/=3 
      AEs (OR = 0.18, 95% CI 0.12-0.28, P < 0.001). In conclusion, our study revealed 
      that, compared with docetaxel, anti-PD-1/PD-L1 antibody therapy improved clinical 
      efficacy and safety in previously treated advanced NSCLC patients. This therapy 
      may be a promising treatment for advanced NSCLC patients.
FAU - Huang, Guanghong
AU  - Huang G
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Sun, Xin
AU  - Sun X
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Liu, Dapeng
AU  - Liu D
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Zhang, Yunfeng
AU  - Zhang Y
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Zhang, Boxiang
AU  - Zhang B
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Xiao, Guodong
AU  - Xiao G
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Li, Xiang
AU  - Li X
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Gao, Xiao
AU  - Gao X
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Hu, Chenhao
AU  - Hu C
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Wang, Meng
AU  - Wang M
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Ren, Hong
AU  - Ren H
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Qin, Sida
AU  - Qin S
AD  - Department Two of Thoracic Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171215
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5790535
OTO - NOTNLM
OT  - Immune checkpoint inhibitor
OT  - NSCLC
OT  - PD-1/PD-L1
OT  - meta-analysis
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2018/02/10 06:00
MHDA- 2018/02/10 06:01
PMCR- 2018/01/09
CRDT- 2018/02/10 06:00
PHST- 2017/07/08 00:00 [received]
PHST- 2017/11/17 00:00 [accepted]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2018/02/10 06:01 [medline]
PHST- 2018/01/09 00:00 [pmc-release]
AID - 23279 [pii]
AID - 10.18632/oncotarget.23279 [doi]
PST - epublish
SO  - Oncotarget. 2017 Dec 15;9(3):4239-4248. doi: 10.18632/oncotarget.23279. 
      eCollection 2018 Jan 9.